Role of Cyclooxygenase-2 in the Generation of Vasoactive Prostanoids in the Rat Pulmonary and Systemic Vascular Beds

Background—Prostanoid synthesis by the cyclooxygenase (COX)-2 pathway plays an important role in inflammation, and recent studies have shown the presence of COX-2 in the normal rat lung. However, the role of COX-2 in the generation of vasoactive prostanoids in the rat is uncertain. In the present study, the hypothesis that synthesis of vasoactive prostanoids via the COX-2 pathway can alter pulmonary and systemic vascular resistance was investigated, and the effects of selective COX-2 inhibitors on pulmonary and systemic responses to the prostanoid precursor arachidonic acid were examined in the anesthetized rat with a recently developed right-heart catheterization technique. Methods and Results—Injections of arachidonic acid caused dose-related increases in pulmonary vascular resistance and decreases in systemic vascular resistance. These responses were attenuated by selective COX-2 inhibitors and a selective COX-1 inhibitor, whereas responses to exogenous prostanoids were not altered. Nimesulide or NS-398 did not alter arachidonic acid–induced platelet aggregation in rat platelet-rich plasma. Western blot analysis and immunostaining showed the expression of both COX isoforms in the rat lung. Conclusions—The results of these experiments suggest that arachidonic acid is converted into vasoactive prostanoids by the COX-2 and COX-1 pathway in the pulmonary and peripheral vascular beds in the rat and that TXA2 is a major prostanoid formed in the normal rat lung.

[1]  R. Harris,et al.  Cyclooxygenase-2 inhibition and renal physiology. , 2002, The American journal of cardiology.

[2]  L. Crofford,et al.  Effects of Selective Cyclooxygenase-2 Inhibition on Vascular Responses and Thrombosis in Canine Coronary Arteries , 2001, Circulation.

[3]  M. Ross,et al.  Cyclooxygenase-1 Participates in Selected Vasodilator Responses of the Cerebral Circulation , 2001, Circulation research.

[4]  L. Dwyer-Nield,et al.  High cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2) contents in mouse lung tumors. , 2000, Carcinogenesis.

[5]  G. FitzGerald,et al.  Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. , 1999, The Journal of pharmacology and experimental therapeutics.

[6]  P. Thompson,et al.  Expression and localization of COX-2 in human airways and cultured airway epithelial cells. , 1999, The European respiratory journal.

[7]  D. Fitzgerald,et al.  Selective cyclooxygenase-2 inhibition by nimesulide in man. , 1998, The Journal of pharmacology and experimental therapeutics.

[8]  C. Koboldt,et al.  Pharmacological analysis of cyclooxygenase-1 in inflammation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[9]  W. Seeger,et al.  Vasoregulatory prostanoid generation proceeds via cyclooxygenase-2 in noninflamed rat lungs. , 1998, The Journal of pharmacology and experimental therapeutics.

[10]  W. Seeger,et al.  Cyclooxygenase isoenzyme localization and mRNA expression in rat lungs. , 1998, American journal of respiratory cell and molecular biology.

[11]  J. Drazen,et al.  Prostaglandin G/H synthase-2 is the constitutive and dominant isoform in cultured human lung epithelial cells. , 1996, The American journal of physiology.

[12]  M. Peters-Golden,et al.  Expression and role of cyclooxygenase isoforms in alveolar and peritoneal macrophages. , 1995, The American journal of physiology.

[13]  B. Kennedy,et al.  Cloning and expression of rat prostaglandin endoperoxide synthase (cyclooxygenase)-2 cDNA. , 1993, Biochemical and biophysical research communications.

[14]  Y. Xia,et al.  Cloning two isoforms of rat cyclooxygenase: differential regulation of their expression. , 1993, Archives of biochemistry and biophysics.

[15]  A. Ford-hutchinson,et al.  Expression of mRNA for cyclooxygenase‐1 and cyclooxygenase‐2 in human tissues , 1993, FEBS letters.

[16]  T. Hla,et al.  Human cyclooxygenase-2 cDNA. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[17]  G. FitzGerald,et al.  Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  D. Dewitt Prostaglandin endoperoxide synthase: regulation of enzyme expression. , 1991, Biochimica et biophysica acta.

[19]  K. Seibert,et al.  The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. , 1990, The Journal of biological chemistry.

[20]  A Ward,et al.  Pentoxifylline , 1987, Drugs.

[21]  P. Kadowitz,et al.  Dependence of the airway and pulmonary vascular effects of arachidonic acid upon route and rate of administration. , 1980, The Journal of pharmacology and experimental therapeutics.

[22]  M. Caton,et al.  Prostaglandins and thromboxanes. , 1979, Progress in medicinal chemistry.

[23]  A. Mathé,et al.  Modification of pulmonary vascular responses to arachidonic acid by alterations in physiologic state. , 1978, The Journal of pharmacology and experimental therapeutics.

[24]  P. Kadowitz,et al.  Effects of arachidonic acid and prostaglandins on lung function in the intact dog. , 1978, Journal of applied physiology: respiratory, environmental and exercise physiology.

[25]  J. Vane,et al.  Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.

[26]  J. Vane,et al.  Cyclooxygenases 1 and 2. , 1998, Annual review of pharmacology and toxicology.

[27]  R. N. Brogden,et al.  Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. , 1994, Drugs.

[28]  M. Holtzman,et al.  Arachidonic acid metabolism in airway epithelial cells. , 1992, Annual review of physiology.

[29]  M. Holtzman,et al.  Arachidonic acid metabolism. Implications of biological chemistry for lung function and disease. , 1991, The American review of respiratory disease.

[30]  B. Samuelsson Prostaglandins and Thromboxanes , 1977, NATO Advanced Study Institutes Series.